ter Haar, E.L.M. et al. 2023. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks. Acta Dermato-Venereologica. 103, (Oct. 2023), adv17752. DOI:https://doi.org/10.2340/actadv.v103.17752.